New drug combo cuts death risk in advanced prostate cancer

Technology Nov 10, 2025

Big news for prostate cancer treatment: a new drug combo—leuprolide plus enzalutamide—cut the risk of death by over 40% in patients with aggressive, recurring cancer, according to the global EMBARK trial.
Nearly 1,000 participants from 17 countries took part, and the results suggest this approach could offer real hope for those facing advanced prostate cancer.

Combo therapy outperformed standard treatment

The combo therapy outperformed standard treatment alone, giving patients longer survival over eight years and highlighting how tailored treatments can make a difference.
Early detection through PSA screenings still matters.
One patient, Suresh Patil, saw his PSA levels drop to undetectable within six months on this regimen—a reminder that new options are making an impact right now.